Hence, our study offers new insights into the post-translational modification (PTM)-mediated drug resistance, and highlights the potential clinical benefits of neddylation agonists in improving the responsiveness of BCR::ABL1 TKIs in CML. Here, BCR is linked to chronic myelogenous leukemia, BCR-ABL1 positive.